# @PennMedicine on Twitter

- **Type:** Text
- **Original URL:** https://twitter.com/PennMedicine/status/1665344401067978753
- **Gondola URL:** https://gondola.cc/posts/7022836-PennMedicine-twitter
- **Posted:** 2023-06-04T13:07:00.000+00:00
- **Account Owner:** Penn Medicine (@PennMedicine) — https://gondola.cc/PennMedicine

## Caption

A new study in @JAMAOnc, led by @LovaSunMD & @CharuAggarwalMD, suggests that a 2-year immunotherapy duration is reasonable for advanced #lungcancer, and indefinite immunotherapy is not associated with improved survival. #NSCLC #ASCO23 https://t.co/sYzlhR39to

## Stats

- **Views:** 0
- **Likes:** 10
- **Shares:** 10
- **Comments:** 0

## Tags

nsclc, asco23, lungcancer

---
Copyright (c) Gondola